Fibromyalgia and related medically unexplained symptoms: A lost link between cardiovascular and nociception modulation

Journal of Musculoskeletal Pain

Volumn 17, Issue 1, 2009, Pages 67-79

  Fontenele, Juvenia Bezerra ^a   Félix, Francisco Hélder Cavalcante ^b  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b Faculdade de Medicina de Juazeiro do Norte   (Brazil)

Author keywords

Central sensitization; Endothelial dysfunction; Fibromyalgia syndrome; Hyperalgesia; Orthostatic intolerance; Pain modulation

Indexed keywords

ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DISEASE ASSOCIATION; DYSAUTONOMIA; FIBROMYALGIA; HUMAN; HYPERALGESIA; MORBIDITY; NOCICEPTION; PAIN; PATHOGENESIS;

EID: 61649091818     PISSN: 10582452     EISSN: 15407012     Source Type: Journal    
DOI: 10.1080/10582450802679904     Document Type: Article

References (116)

1. Nampiaparampil DE, Shmerling RH: A review of fibromyalgia. Am J Manag Care 10: 794-800, 2004.
2. Bernatsky S, Dobkin BL De Civita M, Penrod JR: Comorbidity and physician use in fibromyalgia. Swiss Med Wkly 135: 76-81, 2005.
3. Picavet HSJ, Hoeymans N: Health-related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC-3 study. Ann Rheum Dis 63: 723-729, 2004.
4. Russell IJ: Fibromyalgia syndrome. Bonica's Management of Pain, 3rd Ed. Edited by JD Loeser, SH Butler, CR Chapman, DC Turk. Lippincott Williams & Wilkins Publishers, Philadelphia, PA, 2001.
5. Buckhardt CS, Goldenberg D, Crofford L, Gerwin R, Gowens S, Jackson K, et al.: Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. American Pain Society, Glenview, IL, 2005, pp. 109.
6. Goldenberg DL, Burckhardt C, Crofford L: Management of fibromyalgia syndrome. JAMA 292: 2388-2395, 2004.
7. Ciccone DS, Natelson BH: Comorbid illness in women with chronic fatigue syndrome: A test of the single syndrome hypothesis. Psychosom Med 65: 268-275, 2003.
8. Maiden NL, Hurst NP, Lochhead A, Carson AJ, Sharpe M: Medically unexplained symptoms in patients referred to a specialist rheumatology service: Prevalence and associations. Rheumatology 42: 108-112, 2003.
9. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al.: Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 3: 25, 2003.
10. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A: The chronic fatigue syndrome a comprehensive aproach to its definition and study. Ann Intern Med 121(12): 953-959, 1994.
11. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33: 160-172, 1990.
12. Laske C, Stransky E, Eschweiler GW, Klein R, Wittorf A, Leyhe T, et al.: Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. J Psychiatric Res (in press).
13. Sarchielli P, Alberti A, Candeliere A, Floridi A, Capocchi G, Calabresi P: Glial cell line-derived neurotrophic factor and somatostatin levels in cerebrospinal fluid of patients affected by chronic migraine and fibromyalgia. Cephalalgia 26: 409-415, 2006.
14. Denko CW, Malemud CJ: Serum growth hormone and insulin but not insulin-like growth factor-1 levels are elevated in patients with fibromyalgia syndrome. Rheumatol Int 25: 146-151, 2005.
15. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ: Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskeletal Disord 5: 48, 2004.
16. McCall-Hosenfeld JS, Goldenberg DL, Hurwitz S, Adler GK: Growth hormone and insulin-like growth factor-1 concentrations in women with fibromyalgia. J Rheumatol 30(4): 809-814, 2003.
17. Gursoy S, Erdal E, Herken H, Madenci E, Alaaehirli B, Erdal N: Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 23: 104-107, 2003.
18. Cleare AJ, Miell J, Heap E, Sookdeo E, Young L, Malhi GS, et al.: Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 86: 3545-3554, 2001.
19. Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B: Association of T102C polymorphism of the5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 21: 58-61, 2001.
20. Wallace DJ, Linker-Isralei M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenic role in fibromyalgia: A hypothesis and pilot study. Rheumatology 40: 743-749, 2001.
21. Neeck G: Neuroendocrine and hormonal perturbations and relations to the serotoninergic system in fibromyalgia patients. Scand J Rheumatol 113: 8-12, 2000.
22. Larson AA, Giovengo SL, Russel IJ, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: Implication for nitric oxide pathways. Pain 87: 201-211, 2000.
23. Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, et al.: Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 42: 2482-2488, 1999.
24. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL: Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 106: 534-543, 1999.
25. Klein R, Berg PA: High incidence of antibodies to 5-hydroxytryptamine gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: Evidence for a clinical entity of both disorders. Eur J Med Res 1: 21-26, 1995.
26. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 37: 1593-1601, 1994.
27. McBeth J, Chiu YH, Silman AJ, Ray D, Morris R, Dickens C, et al.: Hypothalamic-pituitary-adrenal stress axis function and the relantionship with chronic widespread pain and its antecedents. Arthritis Res Ther 7: R992-R1000, 2005.
28. Gur A, Cevik R, Sarac AJ, Colpan L, Em S: Hypothalamic-pituitary-gonadal axis and cortisol in young women with fibromyalgia: The potential roles of depression fatigue and sleep disturbance in the occurrence of hypocortisolism. Ann Rheum Dis 63: 1504-1506, 2004.
29. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al.: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37: 1583-1592, 1994.
30. Ehrlich GE: Pain is real; fibromyalgia isn't. J Rheumatol 30: 1666-1667, 2003.
31. Wolfe F: Stop using the American College of Rheumatology criteria in the clinic. J Rheumatol 30: 1671-1672, 2003.
32. Hadler MN: "Fibromyalgia" and the medicalization of misery. J Rheumatol 30: 1668-1670, 2003.
33. Gordon DA: Fibromyalgia. Real or imagined? J Rheumatol 30: 1665, 2003.
34. Werle E, Fischer HP, Muller A, Fiehn W, Eich W: Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 28: 595-600, 2001.
35. Barsky AJ, Borus JF: Functional somatic syndromes. Ann Intern Med 130: 910-921, 1999.
36. Hudson JI, Arnold LM, Keck PE, Auchenback MB, Pope HG: Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry 56: 884-891, 2004.
37. Sayar K, Gulec H, Topbas M, Kalyoncu A: Affective distress and fibromyalgia. Swiss Med Wkly 134: 248-253, 2004.
38. Henningsen P, Zimmerman T, Sattel H: Medically unexplained physical symptoms anxiety and depression: A meta-analytic review. Psychosom Med 65: 528-533, 2003.
39. Procee H: Semiotics and fibromyalgia. Rheumatology 43: 255-257, 2004.
40. Hazemeijer I, Rasker JJ: Fibromyalgia and the therapeutic domain.Aphilosophical study on the origins of fibromyalgia in a specific social setting. Rheumatology 42: 507-515, 2003.
41. Ulas UH, Unlu E, Hamamcioglu K, Odabasi Z, Cakci A, Vural O: Dysautonomia in fibromyalgia syndrome: Sympathetic skin responses and RR interval analysis. Rheumatol Int 26(5): 383-387, 2006.
42. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, et al.: Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 32: 1787-1793, 2005.
43. Goldstein DS, Robertson D, Esler M, Straus SE, Eisenhofer G: Dysautonomias: Clinical disorders of the autonomic nervous system. Ann Intern Med 137: 753-763, 2002.
44. Martínez-Lavín M: Management of dysautonomia in fibromyalgia. Rheum Dis Clin N Am 28: 379-387, 2002.
45. Cohen H, Neumann L, Kotler M, Buskila D: Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. IMAJ 3: 755-760, 2001.
46. Raj SR, Brouillard D, Simpson CS, Hopman WM, Abdollah H: Dysautonomia among patients with fibromyalgia: A noninvasive assesment. J Rheumatol 27: 2660-2665, 2000.
47. Martínez-Lavín M, Hermosillo AG, Mendoza C, Ortiz R, Cajigas JC, Pineda C, et al.: Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 24: 714-718, 1997.
48. Martínez-Lavín M, Hermosillo AG, Rosas M, Soto M: Circadian studies of autonomic nervous balance in patients with fibromyalgia. Arthritis Rheum 41(11): 1966-1971, 1998.
49. Bou-Holaigah I, Rowe PC, Kan J, Calkins H: The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 274: 961-967, 1995.
50. Rowe PC, Bou-Holaigah I, Kan JS, Calkins H: Is neurally mediated hypotension an unrecognised cause of chronic fatigue? Lancet 345: 623-624, 1995.
51. Bou-Holaigah I, Calkins H, Flynn JA, Tunin C, Chang H-C, Kan JS, et al.: Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 15: 239-246, 1997.
52. Furlan R, Colombo S: Síndrome fibromialgica e sistema nervoso autonomo. Progressi in Reumatologia 1: 47-53, 2001.
53. Naschitz JE, Rosner I, Rozenbaum M, Naschitz S, Musafia-Priselac R, Shaviv N, et al.: The head-up tilt test with haemodynamic instability score in diagnosing chronic fatigue syndrome. Q J Med 96: 133-142, 2003.
54. Furlan R, Jacob G, Snell M, Robertson D, Porta A, Harris P, et al.: Chronic orthostatic intolerance. A disorder with discordant cardiac and vascular sympathetic control. Circulation 98: 2154-2159, 1998.
55. Schondorf R, Low PA: Idiopathic postural orthostatic tachycardia syndrome: An attenuated form of acute pandysautonomia? Neurology 43(1): 132-137, 1993.
56. Stewart JM, Weldon A: Vascular perturbations in the chronic orthostatic intolerance of the postural orthostatic tachycardia syndrome. J Appl Physiol 89: 1505-1512, 2000.
57. Novak V, Novak P, Opfer-Gehrking TL, Low PA: Postural tachycardia syndrome: Time frequency mapping. J Auton Nerv Syst 61(3): 313-320, 1996.
58. Low PA, Opfer-Gehrking TL, Textor SC, Schondorf R, Suarez GA, Fealey RD, et al.: Comparison of the postural tachycardia syndrome (POTS) with osthostatic hypotension due to autonomic failure. J Auton Nerv Syst 50(2): 181-188, 1994.
59. Stewart JM: Microvascular filtration is increased in postural tachycardia syndrome. Circulation 107: 2816-2822, 2003.
60. Stewart JM: Pooling in chronic orthostatic intolerance. Arterial vasoconstrictive but not venous compliance defects. Circulation 105: 2274-2281, 2002.
61. Stewart JM, Weldon A: Reflex vascular defects in the orthostatic tachycardia syndrome in adolescents. J Appl Physiol 90: 2025-2032, 2001a.
62. Stewart JM, Weldon A: The relation between lower limb pooling and blood flow during orthostasis in the postural orthostatic tachycardia syndrome of adolescents. J Pediatr 138: 512-519, 2001b.
63. Schondorf R, Benoit J, Stein R: Cerebral autoregulation is preserved in postural tachycardia syndrome. J Appl Physiol 99(3): 828-835, 2005.
64. Jáuregui-Renaud K, Hermosillo JAG, Jardón JL, Márquez MF, Kostine A, Silva MA, et al.: Cerebral blood flow during supine rest and the first minute of head-up tilt in patients with orthostatic intolerance. Europace 7: 460-464, 2005.
65. Hermosillo JAG, Jáuregui-Renaud K, Kostine A, Márquez MF, Lara JL, Cárdenas M: Comparative study of cerebral blood flow between postural tachycardia and neurocardiogenic syncope during head-up tilt test. Europace 4: 369-374, 2002.
66. Jacob G, Atkinson D, Jordan J, Shannon JR, Furlan R, Black BK, et al.: Effects of standing on cerebrovascular resistance in patients with idiopathic orthostatic intolerance. Am J Med 106(1): 59-64, 1999.
67. Jordan J, Shannon JR, Black BK, Paranjape SY, Barwise J, Robertson D: Raised cerebrovascular resistance in idiopathic orthostatic intolerance. Evidence for sympathetic vasoconstriction. Hypertension 32: 699-704, 1998.
68. Backman E, Bengtsson A, Bengtsson M, Lennmarken C, Henriksson KG: Skeletal muscle function in primary fibromyalgia. Effect of regional sympathetic blockade with guanethidine. Acta Neurol Scand 77: 187-191, 1988.
69. Vaeroy H, Qiao ZG, Morkrid L, Forre O: Altered sympathetic nervous system response in patients with fibromyalgia (fibrositis syndrome). J Rheumatol 16: 1460-1465, 1989.
70. Stewart JM, Gewitz MH, Weldon A, Arlievsky N, Li K, Munoz JL: The nature of orthostatic intolerance in adolescents with the chronic fatigue syndrome. Pediatrics 103: 116-121, 1999.
71. Stewart JM, Weldon AA, Munoz JL: Pattern of orthostatic intolerance: The orthostatic tachycardia syndrome and adolescent chronic fatigue. J Pediatr 135: 218-225, 1999.
72. Farquhar WB, Taylor A, Darling SE, Chase KP, Freeman R: Abnormal baroreflex responses in patients with idiopathic orthostatic intolerance. Circulation 102: 3086-3091, 2000.
73. Jacob G, Costa F, Shannon JR, Robertson RM, Wathen M, Stein M, et al.: The neuropathic postural tachycardia syndrome. N Engl J Med 343: 1008-1014, 2000.
74. Jacob G, Robertson D, Mosqueda-Garcia R, Ertl AC, Robertson RM, Biaggioni I: Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. Am J Med 103: 128-133, 1997.
75. Robertson D, Hollister AS, Biaggioni I, Netterville JL, Mosqueda-Garcia R, Robertson RM: The diagnosis and treatment of baroreflex failure. N Engl J Med 329: 1449-1455, 1993.
76. Garland EM, Winker EM, Williams SM, Jiang L, Stanton K, Byrne DW, et al.: Endothelial NO synthase polymorphisms and postural tachycardia syndrome. Hypertension 46: 1103-1110, 2005.
77. Clifford PS, HellstenY: Vasodilatory mechanisms in contracting skeletal muscle. J Appl Physiol 97: 393-403, 2004.
78. Winker R, Garland E, Rudiger H, Diedrich A, Biaggioni I, Ponocny I, et al.: Influence of an insertion variant in the 5′ UTR of the endothelin gene on orthostatic intolerance. Am J Med Sci 330(4): 166-171, 2005a.
79. Popowski K, Sperker B, Kroemer HK, John U, Laule M, Stangl K, et al.: Functional significance of a hereditary adenine insertion variant in the 5′-UTR of the endothelin-1 gene. Pharmacogenetics 13(8): 445-451, 2003.
80. Jacob G, Garland EM, Costa F, Stein CM, Xie HG, Robertson RM, et al.: β-2 adrenoceptor genotype and function affect hemodynamic profile heterogeneity in postural tachycardia syndrome. Hypertension 47: 421, 2006.
81. Winker R, Barth A, Valic E, Maier R, Osterode W, Pilger A, et al.: Functional adrenergic receptor polymorphisms and idiopathic orthostatic intolerance. Int Arch Occup Environ Health 78(3): 171-177, 2005b.
82. Tabara Y, Kohara K, Miki T: Polymorphisms of genes encoding components of the sympathetic nervous system but not the renin-angiotensin system as risk factors for orthostatic hypotension. JHypertens 20(4): 651-656, 2002.
83. Behnke BJ, Padilla DJ, Ferreira LF, Delp MD, Musch TI, Poole DC: Effects of arterial hypotension on microvascular oxygen exchange in contracting skeletal muscle. J Appl Physiol 100: 1019-1026, 2006.
84. Stewart JM, Medow MS, Montgomery LD, McLeod K: Decreased skeletal muscle pump in patients with postural tachycardia syndrome and low peripheral blood flow. Am J Physiol Heart Circ Physiol 286: 1216-1222, 2004.
85. Staud R, Vierck CJ, Robinson ME, Price DD: Spatial summation of heat pain within and across dermatomes in fibromyalgia patients and pain-free subjects. Pain 111: 342-350, 2004.
86. Staud R, Robinson ME, Vierck CJ Jr, Cannon RL, Mauderli AP, Price DD: Ratings of experimental pain and pain-related negative affect predict clinical pain in patients with fibromyalgia syndrome. Pain 105: 215-222, 2003.
87. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD: Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91: 165-171, 2001.
88. Brain SD, Grant AD: Vascular actions of calcitonin-related peptide and adrenomedullin. Physiol Rev 84: 903-934, 2004.
89. Hinson JP, Kapas S, Smith DM: Adrenomedullin a multifunctional regulatory peptide. Endocr Rev 21(2): 138-167, 2000.
90. Subhash MN, Nagaraja MR, Sharada S, Vinod KY: Cortinal alpha-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochem Int 43: 603-609, 2003.
91. Tolk J, Kohnen R, Muller W: Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol 119: 72-75, 2004.
92. Farber L, Stratz TH, Bruckle W, Spath M, Pongratz D, Lautenschlager J, et al.: Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized double-blind placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 21(1): 1-13, 2001.
93. Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA: Treatment of fibromyalgia with tropisetron a 5HT3 serotonin antagonist: A pilot study. Clin Rheumatol 19(1): 6-8, 2000.
94. Jasmin L, Tien D, Weinshenker D, Palmiter RD, Green PG, Janni G, et al.: The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc Natl Acad Sci USA 99: 1029-1034, 2002.
95. Sagen J, Proudfit HK: Effect of intrathecally administered noradrenergic antagonists on nociception in the rat. Brain Res 310: 295-301, 1984.
96. Siddall PJ, Molloy AR, Walker S, Mather LE, Rutkowski SB, Cousins MJ: The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg 91: 1493-1498, 2000.
97. Mendez R, Eisenach JC, Kashtan K: Epidural clonidine analgesia after cesarean section. Anesthesiology 73: 848-852, 1990.
98. Maes M, Libbrecht I, Delmeire L, Lin A, De Clerk L, Scharpe S, et al.: Changes in platelet alpha-2-adrenoceptors in fibromyalgia: Effects of treatment with antidepressants. Neuropsychobiology 40(3): 129-133, 1999.
99. Campbell TS, Ditto B, Séguin JR, Sinray S, Tremblay RE: Adolescent pain sensitivity is associated with cardiac autonomic function and blood pressure over 8 years. Hypertension 41: 1228-1233, 2003.
100. Ghione S: Hypertension-induced hypalgesia. Evidence in experimental animals and humans pathophysiological mechanisms and potential clinical consequences. Hypertension 28: 494-504, 1996.
101. Dworkin B, Filewich R, Miller N, Craigmyle N, Pickering T: Baroreceptor activation reduces reactivity to noxious stimulation: Implications in hypertension. Science 205: 1299-1301, 1979.
102. Thurston CL, Randich A: Effects of vagal afferent stimulation on ON and OFF cells in the rostroventral medulla: Relationships to nociception and arterial blood pressure. J Neurophysiol 67(1): 180-196, 1992.
103. Randich A, Ren K, Gebhart GF: Electrical stimulation of cervical vagal afferent II. Central relays for behavioral antinociception and arterial blood pressures decreases. J Neurophysiol 64(4): 1115-1124, 1990.
104. Hagen K, Zwart JA, Holmen J, Svebak S, Bovim G, Stovner LJ: Does hypertension protect against chronic musculoskeletal complaints? Arch Int Med 165(8): 916-922, 2005.
105. Shimoda O, Ikuta Y: The current perception thresholds vary between horizontal and 70° tilt-up positions. Anest Analg 91: 398-402, 2000.
106. Guasti L, Grimoldi P, Diolisi A, Petrozzino MR, Gaudio G, Grandi AM, et al.: Treatment with enalapril modifies the pain perception pattern in hypertensive patients. Hypertension 31: 1146-1150, 1998.
107. Jeschonneck M, Grohmann G, Hein G, Sprott H: Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology 39: 917-921, 2001.
108. Koltyn KF, Umeda M: Exercise hypoalgesia and blood pressure. Sports Med 36(3): 207-214, 2006.
109. Pyke KE, Tschakovsky ME: The relationship between shear stress and flow-mediated dilation: Implications for the assessment of endothelial function. J Physiol 568: 357-369, 2005.
110. Faulx MD, Wright AT, Hoit BD: Detection of endothelial dysfunction with brachial artery ultrasound scanning. Am Heart J 145: 943-951, 2003.
111. Lange FP, Kalkman JS, Bleijenberg G, Hagoort P, van der Werf SP, van der Meer JWM, et al.: Neural correlates of the chronic fatigue syndrome - an fMRI study. Brain 127(9): 1948-1957, 2004.
112. Schmaling KB, Lewis DH, Fiedelak JI, Mahurin R, Buchwald DS: Single-photon emission computerized tomography and neurocognitive function in patients withchronic fatigue syndrome. Psychosom Med 65: 129-136, 2003.
113. Lewis DH, Mayberg HS, Fischer ME, Goldberg J, Ashton S, Graham MM, et al.: Monozygotic twins discordant for chronic fatigue syndrome: Regional cerebral blood flow SPECT. Radiology 219: 766-773, 2001.
114. Schwartz RB, Garada BM, Komaroff AL, Tice HM, Gleit M, Jolesz FA, et al.: Detection of intracranial abnormalities in patients with chronic fatigue syndrome: Comparison of MR Imaging and SPECT. Am J Roentgen 162: 935-941, 1994.
115. Razumovsky AY, DeBusk K, Calkins H, Snader S, Lucas KE, Vyas P, et al.:Cerebral and systemic hemodynamics changes during upright tilt in chronic fatigue syndrome. J Neuroimaging 13: 57-67, 2003.
116. Tanaka H, Matsushima R, Tamai H, Kajimoto Y: Impaired postural cerebral hemodynamics in young patients with chronic fatigue with and without orthostatic intolerance. J Pediatr 140(4): 412-417, 2002.